Cognetivity Neurosciences Ltd. announced that it has reached a commercial agreement with brain health supplements provider Conka. The new agreement between Cognetivity and Conka will see Cognetivity act as Conka's technology partner. Cognetivity's cutting-edge brain health assessment technology will be made available to Conka's customers so that they can sensitively and accurately measure changes in their cognitive performance, helping them to optimize their mental and physical state and to guard against the risks of head injuries and concussion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | -25.00% | 0.00% | 0.00% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 1.03M | |
+5.85% | 32.93B | |
+20.16% | 7.94B | |
+30.81% | 4.19B | |
-25.95% | 2.8B | |
-19.96% | 1.38B | |
-31.87% | 1.17B | |
+8.02% | 966M | |
-35.73% | 900M | |
-25.74% | 839M |
- Stock Market
- Equities
- CGN Stock
- News Cognetivity Neurosciences Ltd.
- Cognetivity Neurosciences Enters Commercial Agreement with Conka